Precision Medicine in Oncology®

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

Latest News

The FDA granted accelerated approval to repotrectinib (Augtyro) for adult and pediatric patients aged 12 years and older with solid tumors harboring a NTRK gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed after treatment or have no satisfactory alternative therapy.
FDA Grants Accelerated Approval to Repotrectinib for NTRK+ Solid Tumors

June 13th 2024

The FDA granted accelerated approval to repotrectinib (Augtyro) for select patients with solid tumors harboring a NTRK gene fusion.

FDA Grants Full Approval to Selpercatinib for RET+ Thyroid Cancer
FDA Grants Full Approval to Selpercatinib for RET+ Thyroid Cancer

June 12th 2024

Fabrice Barlesi, MD, PhD
Adjuvant Alectinib Approved in Europe for ALK+ Early-Stage NSCLC

June 10th 2024

Lydia Pace, MD, MPH
A Geneticist and PCP Detail Considerations With New Screening Recommendations for Breast Cancer

June 5th 2024

Here is your guide to important regulatory approvals made by the FDA in May 2024.
OncLive’s May Roundup of Key FDA Approvals in Oncology

May 31st 2024